Shots: :stohththShots:

• The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. The collaboration will deploy Lonza’s global expertise in technology transfer and manufacturing while the technology transfer expected to begin in Jun’2020
• The focus of the collaboration is to enable the manufacturing of mRNA-1273 up to 1B doses/year and anticipates the manufacturing of the first batches of mRNA-1273 at Lonza US site in Jul’2020- assuming the currently expected dose of 50µg
• Manufacturing operations at Lonza US site is covered by Moderna’s agreement with BARDA under which BARDA will support late-stage clinical development programs of mRNA-1273. On Apr 27- 2020- Moderna has submitted IND to the US FDA for P-II studies with its expected initiation in Q2’20

Click here ­to­ read full press release/ article | Ref: Moderna | Image: Moderna

Related News:  BARDA Grants ~ $483M to Moderna for Accelerating the Development of mRNA-1273 Against COVID-19